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pertensive patients.We recruited hypertensive patients from a cardiovascular clinic in a tertiary
medical center in Taiwan. All received standard 12-lead electrocardiogramexamination. QTpro-
longation was defined as QTc interval 440 ms in men or 450 ms in women. High-sensitive CRP
kits were used for the measurement of the CRP levels. A total of 466 consecutive patients were
finally enrolled. Mean age was 60.6  12.0 years. CRP level was correlated with QTc interval
(p< 0.001) and presence ofQTprolongation (pZ 0.014). Multivariate regression analysis showed
that CRP level (pZ 0.001), age (pZ 0.004), sex (p < 0.001), height (pZ 0.001), low-density li-
poprotein (pZ 0.041), and QRS interval (p< 0.001) were associated with QTc interval. Further-
more, CRP level [odds ratio (OR) Z 1.203, 95% confidence interval (CI) Z 1.027e1.410,
p Z 0.022], age (OR Z 1.040, 95% CI Z 1.010e1.071, p Z 0.009), waist (OR Z 1.033, 95%
CIZ 1.000e1.066, pZ 0.047), triglyceride (ORZ 0.993, 95% CIZ 0.987e0.999, pZ 0.021)
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ence of QT prolongation, it could be considered in the risk assessment for hypertensive patients.
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Framingham risk score, using age, sex, cholesterol, hyper-
tension, and smoking, as a tool to assess the risk of coronary
heart disease (CHD) has been used for decades. However,
Framingham risk score tends to falsely reassure persons
deemed to be at low risk [1,2]. The addition of laboratory
testing to the traditional risk factors has been suggested to
improve the 10-year risk assessment [3]. C-reactive protein
(CRP) is the most extensively studied of numerous inflam-
matory biomarkers potentially linked to underlying
atherosclerosis and subsequent cardiovascular disease
(CVD). Several meta-analyses have found a significant
relationship between baseline serum CRP and subsequent
CHD or CVD [4e11]. Evaluation of CRP values in predicting
the likelihood of CHD has been recommended [12]. CRP had
ever been considered as a probable risk assessment
biomarker for those with metabolic syndrome and hyper-
tension [13].
QT interval is the time from the start of the Q wave to
the end of the T wave in the electrocardiogram and rep-
resents the beginning of ventricular depolarization to the
end of ventricular repolarization. Prolongation of cor-
rected QT (QTc) interval is associated with an increased
risk of life-threatening cardiac arrhythmia and sudden
death [14]. Furthermore, hypertension is known to be
associated with an increased prevalence of prolonged QTc
interval [15].
Although CRP and QTc interval are independent risk
factors for hypertensive patients, few studies have re-
ported the association between CRP and QTc interval in
these patients [16]. In this study, our aim was to investi-
gate the correlation of CRP, QTc interval and presence of
QTc prolongation in hypertensive patients who are known
as the high-risk population for future cardiovascular dis-
ease [17].
Materials and methods
Patient characteristics
This population-based cross-sectional study was conducted
from January 2007 to December 2009. In total, 466 patients
with hypertension followed at a cardiovascular clinic in a
tertiary medical center in Taiwan were enrolled in the
study. The inclusion criteria were: (1) diagnosed as essen-
tial hypertension; and (2) with regular cardiovascular
outpatient clinic follow-up for at least 6 months. Exclusion
criteria were: (1) patients with CRP > 10 mg/dL; and (2)
patients who suffered from acute illness at the time of
enrollment.Measurements
Study participants underwent a detailed review of their
medical history consisting of patients’ age, sex, height,
weight, body mass index, and waist. Biochemistry labora-
tory measurements were done included fasting glucose, 2
hours postprandial glucose, glycated hemoglobin, blood
urea nitrogen, blood creatinine, albumin, urine albumin
and complete lipid profiles including total cholesterol, tri-
glyceride, low- (LDL) and high-density lipoprotein, and
antihypertension drugs including diuretic and beta blocker
and statin. All measurements were analyzed at the central
laboratory of Kaohsiung Medical University Hospital, Kaoh-
siung, Taiwan. High-sensitivity CRP kits were used to mea-
sure CRP levels.Definition and calculation
Hypertensive patients were diagnosed based on hyperten-
sion guidelines when systolic blood pressure is  140 mmHg,
diastolic blood pressure is  90 mmHg, or patients who
received hypertension drugs.
QT interval is the time from the start of the Q wave to
the end of the T wave in the electrocardiogram. The QT
interval and ReR interval were automatically measured on
a computer screen using a digital caliper at a screen rate of
100 mm/second. The means of the QT intervals and ReR
intervals were obtained by measuring the QT intervals and
ReR intervals of three consecutive beats in each lead. The
QT interval is dependent on the heart rate: the faster the
heart rate the shorter of the QT interval. We used Bazett’s
formula to calculate heart rate-corrected QT interval:
maximal mean QT interval/(mean ReR interval)0.5. QTc
prolongation was defined as QTc interval 440 ms in men
and 450 ms in women [16].Statistical analysis
All continuous data were expressed as mean  standard
deviation. Chi-square test and Wilcoxon rank-sum test were
used to compare categorical data and nonparametric data
respectively. The t test was used for analysis between
continuous variables. Multiple and binary regression anal-
ysis were used to adjust the covariates. Age, sex, height,
QRS, CRP, and LDL were added into multiple regression
analysis. Age, waist, QRS, CRP, and triglyceride were added
into binary regression analysis for adjustment. All tests
were two-sided, and the level of significance was estab-
lished as p < 0.05.
Table 2 Correlation between baseline characteristics and
QTc interval.
Characteristic r p
Age 0.242 <0.001
Sex d <0.001
Height 0.194 <0.001
Weight 0.115 0.013
BMI 0.010 0.822
Waist 0.019 0.682
QRS 0.232 <0.001
CRP 0.170 <0.001
HbA1C 0.038 0.407
Fasting glucose 0.024 0.603
Postprandial glucose 0.130 0.005
Total cholesterol 0.072 0.122
Triglyceride 0.036 0.442
LDL-cholesterol 0.124 0.008
HDL-cholesterol 0.070 0.133
Albumin 0.129 0.005
BUN 0.055 0.237
Blood creatinine 0.007 0.887
Urine albuminuria 0.043 0.352
Statin d 0.822
Diuretics d 0.092
b-blocker d 0.152
BMIZ body mass index; BUN Z blood urea nitrogen; CRPZ C-
reactive protein; HbA1C Z glycated hemoglobin; HDL Z high-
density lipoprotein; LDL Z low-density lipoprotein.
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The study group consisted of 466 consecutive hypertensives
and 250 (53.6%) participants were men. Ages ranged from
26 years to 91 years (mean, 60.55  12.04 years). QTc in-
terval ranged from 277 ms to 563 ms. Overall, 43 patients
(9.23%) were found to have QTc prolongation.
Baseline characteristics between those with and
without QT prolongation
Table 1 demonstrates the characteristics between patients
with normal and prolonged QTc interval. Comparing to
those with normal QTc interval, patients with QTc prolon-
gation were significantly older (age 66.66  12.71 years vs.
59.93  11.81 years, p < 0.001), had increased waist
(94.27  12.25 cm vs. 90.62  10.78 cm, pZ 0.038), higher
CRP (2.43  1.96 mg/L vs. 1.72  1.78 mg/L, p Z 0.014),
blood urea nitrogen (18.67  7.72 mg/dL vs.
15.68  8.81 mg/dL, p Z 0.032), and blood creatinine
(1.09  0.50 mg/dL vs. 0.92  0.27 mg/dL, pZ 0.033). The
percentages of use of statin, diuretic, and b-blocker were
similar between the two groups.
Correlation between baseline characteristics and
QTc interval
Table 2 demonstrates that the QTc interval was positively
correlated with QRS interval (r Z 0.232, p < 0.001), CRP
(rZ 0.170, p < 0.001), and age (rZ 0.242, p < 0.001). TheTable 1 Baseline characteristics of patients divided into normal and prolongation of corrected QT interval.
Characteristic Total (n Z 466) Normal (n Z 423) Prolongation (n Z 43) p
Age, y 60.55  12.04 59.93  11.81 66.66  12.71 <0.001
Male 250 (53.6) 227 (53.57) 23 (53.5) 0.982
Height, cm 160.96  8.22 161.08  8.24 159.83  8.01 0.345
Weight, kg 69.60  12.15 69.57  12.01 69.88  13.59 0.872
BMI, kg/m2 26.79  3.83 26.73  3.67 27.41  5.22 0.410
Waist, cm 90.96  10.96 90.62  10.78 94.27  12.25 0.038
QRS, ms 87.61  14.72 86.30  12.72 100.56  24.14 <0.001
CRP, mg/L 1.79  1.80 1.72  1.78 2.43  1.96 0.014
Fasting glucose, mg/dL 113.90  24.67 114.19  24.81 111.16  23.38 0.444
Postprandial glucose, mg/dL 141.95  51.94 141.22  52.39 147.07  47.42 0.346
HbA1C, % 6.10  0.90 6.10  0.89 6.15  0.98 0.737
Total cholesterol, mg/dL 187.76  41.87 188.97  41.94 175.86  39.72 0.050
Triglyceride, mg/dL 138.21  82.87 140.59  84.72 114.81  57.48 0.052
LDL-cholesterol, mg/dL 111.67  34.20 112.62  34.06 102.32  34.52 0.060
HDL-cholesterol, mg/dL 42.80  20.46 42.55  20.96 45.30  14.50 0.401
Albumin, g/dL 4.28  0.26 4.29  0.26 4.22  0.28 0.107
BUN, mg/dL 15.96  8.75 15.68  8.81 18.67  7.72 0.032
Blood creatinine, mg/dL 0.93  0.30 0.92  0.27 1.09  0.50 0.033
Urine albuminuria, mg/g 43.12  148.90 42.01  151.38 53.97  122.84 0.616
Statin 171 (36.7) 155 (36.6) 16 (37.2) 0.941
Diuretics 232 (49.8) 207 (48.9) 25 (58.1) 0.250
b-blocker 310 (66.5) 284 (67.1) 26 (60.5) 0.377
Data are presented as n (%) or mean  SD, unless otherwise indicated.
BMI Z body mass index; BUN Z blood urea nitrogen; CRP Z C-reactive protein; HbA1C Z glycated hemoglobin; HDL Z high-density
lipoprotein; LDL Z low-density lipoprotein.
Table 4 Independent predictors of QT prolongation in
binary logistic regression analysis.
Characteristic OR 95% CI p
C-reactive protein and QT in hypertension 313QTc interval was negatively correlated with height
(r Z 0.194, p < 0.001), weight (r Z 0.115, p Z 0.013),
LDL (r Z 0.124, p Z 0.008), and albumin (r Z 0.129,
p Z 0.005).CRP 1.203 1.027e1.410 0.022
QRS 1.046 1.028e1.065 <0.001
Age 1.040 1.010e1.071 0.009
Waist 1.033 1.000e1.066 0.047
Triglyceride 0.993 0.987e0.999 0.021
CIZ confidence interval; CRPZ C-reactive protein; ORZ odds
ratio.Independent predictors in regression analysis
Multivariable model showed that CRP (p Z 0.001), QRS in-
terval (p < 0.001), LDL (p < 0.041), age (p Z 0.004), sex
(p < 0.001), and height (p Z 0.001) were independent
predictors for QTc interval (Table 3). Binary logistic
regression analysis demonstrated that age [odds ratio
(OR)Z 1.040; 95% confidence interval (CI)Z 1.010e 1.071;
p Z 0.009], waist (OR Z 1.033; 95% CI Z 1.000e1.066;
p Z 0.047), CRP (OR Z 1.203; 95% CI Z 1.027e1.410;
p Z 0.022), QRS (OR Z 1.046; 95% CI Z 1.028e1.065;
p < 0.001), and triglyceride (OR Z 0.993; 95%
CI Z 0.987e0.999; p Z 0.021) were significantly indepen-
dent predictors of QTc prolongation in the hypertensive
patients (Table 4).Discussion
There were three major findings in this cross-sectional
study in hypertensive patients. First, CRP is a significant
predictor for the QTc interval and presence of QT prolon-
gation. Second, age is also an independent factor associ-
ated with QT parameters in the hypertensive patients.
Third, waist is independently associated with the presence
of QT prolongation.
Hypertension is one of the well-known risk factors of
coronary heart disease in the Framingham risk score [1,2].
Patients with hypertension and especially those with left
ventricular hypertrophy are at an increased risk of sudden
cardiac death [18e20]. QT interval is a measure of the
duration of ventricular depolarization and repolarization.
Some studies demonstrate the correlation with QTc interval
and hypertension. Akintunde et al. [15] showed that
maximum QTc interval were significantly higher among
patients with hypertension than that without hypertension.
Mozos and Serban [21] concludes that hypertension is
associated with an increased prevalence of prolonged QT
interval and left ventricular hypertrophy is associated with
prolonged QT interval. Because prolonged QTc interval is
associated with an increased risk of life-threatening cardiac
arrhythmia and sudden death, it is mandatory to findTable 3 Independent predictors of QTc interval in multi-
variate regression analysis.
Coefficient Standard error T p
CRP 2.494 0.724 3.446 0.001
QRS 0.474 0.091 5.231 <0.001
Age 0.344 0.120 2.880 0.004
Sex 13.398 2.739 4.892 <0.001
Height 0.593 0.176 3.379 <0.001
LDL 0.080 0.039 2.054 <0.041
CRP Z C-reactive protein; LDL Z low-density lipoprotein.factors associated with QTc interval and QT prolongation in
hypertensive patients [14].
Inflammation is central to the initiation and progression
of atherosclerosis and to triggering CVD events [22]. CRP is
the most extensively studied inflammatory biomarker
potentially linked to underlying atherosclerosis and subse-
quent CVD. The Multiple Risk Factor Intervention Trial was
the first of many primary prevention, prospective epide-
miological studies to show a strong relationship between
levels of CRP and mortality from CHD in high-risk middle-
aged men [23]. In the Women’s Health Study, CRP was a
stronger predictor of cardiovascular events than LDL-C,
which is an established causative biological marker of
atherosclerosis [24]. The correlation between CRP and QTc
has been demonstrated in two studies. Kazumi et al. [25]
showed that CRP is independently related to QTc interval
in young apparently healthy men. Kim et al. showed that
prolonged QTc interval in middle aged men and women is
associated with the elevated CRP, independent of con-
founding factors [16]. CRP had been suggested as a risk
assessment biomarker for hypertensive patients [26].
However, there is no study to investigate the correlation
between CRP and QTc interval in the hypertensive patients.
Our research first found that CRP is an independent pre-
dictor of QTc interval and presence of QT prolongation in
hypertensive patients.
Some cross-sectional population studies have investi-
gated the impact of age on QTc interval and showed that
QTc interval prolonged with increasing age [27,28]. Our
previous longitudinal study also showed that maximal QTc
interval significantly increased during a 4-year follow up in
healthy elders [29]. Compatible with previous study, our
research also demonstrates a positive correlation between
age and QTc interval in the hypertensive patients.
Obesity causes significant abnormalities in cardiac
morphology including left atrial enlargement, left ventric-
ular geometric changes and diastolic dysfunction [30e33].
In addition to morphological changes, obesity may lead to
atrial and ventricular repolarization anomalies and QT in-
terval prolongation [34, 35]. Although both QT prolongation
and obesity are associated with ventricular arrhythmia and
sudden cardiac death, the relationship between obesity
and QTc interval prolongation is not clear. Arslan et al. [35]
observed that QTc interval in young men with uncompli-
cated obesity is longer than in healthy individuals. Park and
Swan [36] showed that QTc interval positively associated
with upper body obesity in premenopausal women. In our
study, there is a positive correlation between waist and the
314 K.-T. Chang et al.presence of prolonged QTc interval. These results may
imply that central obesity correlates with abnormal elec-
trical activity in hypertensive patients. Because studies
have demonstrated that weight loss may shorten QTc in-
terval, body weight control may provide additional benefit
for the hypertensive patients [37e40].
Several limitations of our study should be considered.
First, in this cross-sectional study, the results are primarily
hypothesis-generating findings, rather than conclusive re-
sults. Therefore, enrollment of more patients for pro-
pensity score matching and a longitudinal study are needed
to confirm the hypothesis. Second, 466 hypertension pa-
tients were recruited from a tertiary medical center, se-
lection bias could exist and our patients may not represent
the general population. Third, hypertensive patients in this
study were not medication naı¨ve. It is well known that
several medications such as statin, b-blocker, and diuretics
can influence CRP levels. However, we found that use of
above-mentioned drugs was not related with QT
parameters.
In conclusion, because CRP is an independent predictor
of QTc interval and presence of QT prolongation in the
hypertensives, it could be considered in the risk assessment
for the hypertensives.Acknowledgments
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